

Natco Pharma to acquire US-based Dash Pharmaceuticals

14 December 2021 | News

Dash markets, sells, and distributes generic pharmaceutical products



Hyderabad-based NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements.

Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of \$15 million for the year ending December 2021.

This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.